Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea Biotherapeutics, Inc. (not Spyre Therapeutics, Inc.) on March 16, 2022. The report discloses a change in the Company's principal accounting officer and corporate controller.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Resignation: Steven Weber, Vice President and Corporate Controller (Principal Accounting Officer), notified the Company of his resignation, effective March 25, 2022.
- Appointment: Jonathan Alspaugh, Chief Financial Officer, was appointed as the new Principal Accounting Officer, effective immediately on March 17, 2022.
Management Commentary and Risks
Mr. Alspaugh has served as CFO since July 2021. His background includes roles at Evercore (Managing Director) and Barclays Capital. The filing states there are no arrangements or understandings regarding his appointment, no family relationships with directors or officers, and no material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the effective date of Steven Weber's departure (March 25, 2022).
- Confirm Jonathan Alspaugh's immediate assumption of the Principal Accounting Officer role.
- Review subsequent filings for any impact on the Company's financial reporting timeline due to the transition.